We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+28.21%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.31B
AUM Growth
+$110M
(+9.2%)
Cap. Flow
-$90.6M
Cap. Flow
% of AUM
-6.94%
Top 10 Holdings %
Top 10 Hldgs %
78.43%
Holding
36
New
9
Increased
2
Reduced
10
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Solid Biosciences
SLDB
|
+$60.5M |
| 2 |
TG Therapeutics
TGTX
|
+$31.6M |
| 3 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$17.9M |
| 4 |
Gyre Therapeutics
GYRE
|
+$12.8M |
| 5 |
CLSD
Clearside Biomedical
CLSD
|
+$12.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$75.3M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$48.8M |
| 3 |
InflaRx
IFRX
|
+$33.1M |
| 4 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
+$22.7M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
+$17.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Krystal Biotech
KRYS
$10.7B
| $5M | 0.38% |
496,071
-203,929
| -29% | -$2.01M |
|
|
CBIO
27
Crescent Biopharma
CBIO
$546M
| $4.12M | 0.32% |
+2,535
| New | +$5.27M |
|
28
Protara Therapeutics
TARA
$214M
| $3.34M | 0.26% |
33,437
| – | – |
|
|
GTHX
29
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $1.48M | 0.11% |
40,000
-119,780
| -75% | -$3.2M |
|
30
PDS Biotechnology
PDSB
$37.4M
| $337K | 0.03% |
+14,275
| New | +$3.84M |
|
|
CTIC
31
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $222K | 0.02% |
+56,951
| New | +$200K |
|
32
argenx
ARGX
$55.2B
| – | – |
-75,816
| Closed | -$4.79M |
|
|
KDMN
33
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – |
-6,269,342
| Closed | -$22.7M |
|
|
CHMA
34
DELISTED
Chiasma, Inc. Common Stock
CHMA
| – | – |
-1,176,806
| Closed | -$2M |
|
|
ACHN
35
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-585,890
| Closed | -$1.69M |
|
|
CMTA
36
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| – | – |
-585,403
| Closed | -$11.1M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q1 2018 Portfolio in Review
As of Q1 2018, RA Capital Management held 36 positions worth $1.31B, up 9.2% from $1.2B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
RA Capital Management withdrew a net $90.6M in Q1 2018, closing 5 positions and reducing 10 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $22.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.
Against the trend, RA Capital Management opened a new position in Solid Biosciences worth $20.2M.
- RA Capital Management's largest Q1 2018 buy was Solid Biosciences: 179,296 shares worth $20.2M.
- RA Capital Management added most to Ra Pharmaceuticals, Inc. Common Stock in Q1 2018, an estimated $17.9M increase.
- RA Capital Management's biggest Q1 2018 reduction was Ascendis Pharma A/S, cutting an estimated $75.3M.
- RA Capital Management fully exited Kadmon Holdings, Inc. in Q1 2018, selling an estimated $22.7M.
- RA Capital Management's ten largest holdings make up 78% of its $1.31B portfolio in Q1 2018.
- RA Capital Management opened 9 new positions and closed 5 in Q1 2018.
- RA Capital Management's portfolio value rose 9.2% quarter-over-quarter to $1.31B.
Based on RA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.